PhaseBio Pharmaceuticals picks up $40 mln Series C

Malvern, Pennsylvania-based PhaseBio Pharmaceuticals Inc, which is focused on developing treatments for metabolic and specialty cardiopulmonary disorders, has secured $40 million in Series C funding. AstraZeneca led the round with participation from New Enterprise Associates, Hatteras Venture Partners, Johnson & Johnson Innovation – JJDC and Fletcher Spaght Ventures. In addition to the funding, Dr. Michael Gutch of AstraZeneca has been added to PhaseBio’s board of directors while Donald Dwyer, also of AstraZeneca, has become a board observer.

Biotech company ORIG3N scores $3.1 mln

Boston-based biotech company ORIG3N has closed $3.1 million in funding. The investors included Hatteras Venture Partners, Harris & Harris Group, KTB and Mountain Group Capital.


LTI picks up $20 mln Series A

Cambridge, Massachusetts-based Lysosomal Therapeutics Inc, which develops molecules to treat neurodegenerative diseases, has closed $20 million in Series A funding. The backers in this round included Atlas Venture, Hatteras Venture Partners, Lilly Ventures, Sanofi-Genzyme BioVentures, Roche Venture Fund, Partners Innovation Fund and Orion Equity Partners.


Clinipace picks up $50 mln

Morrisville, North Carolina-based Clinipace Worldwide, a digital clinical research organization, has raised $50 million in funding. Virgo Investment Group led the round with participation from other investors that included Crestline Investors, Morgan Stanley Expansion Capital, Hatteras Venture Partners, Harbert Venture Partners and Mario Family Funds. Perella Weinberg Partners served as an advisor on the transaction.


Viamet Pharma raises $60 mln

Viamet Pharmaceuticals Holdings said Tuesday it closed a $60 million Series D financing provided by Brandon Point Industries Ltd. working with Woodford Investment Management. Current investors includes Novartis Venture Fund, Lilly Ventures, Hatteras Venture Partners, Intersouth Partners, Lurie Holdings and Astellas Venture Management. Durham, N.C.-based Viamet Pharma develops antifungal agents using a metalloenzyme medicinal chemistry platform.


Clearside Biomedical picks up $16 mln Series B

Clearside Biomedical said Monday that it has raised $16 million in Series B financing. The investors included RusnanoMedInvest, Hatteras Venture Partners, Santen Pharmaceuticals Co. Ltd., Mountain Group Capital and Georgia Research Alliance Venture Fund. Headquartered in Alpharetta, GA, Clearside Biomedical is a clinical-stage biopharmaceutical firm focused on treating eye diseases.


Edison Partners and Hatteras Venture Partners back Clinverse

Edison Partners said Tuesday that it is leading a $9 million funding round in Clinverse. Other investors include Hatteras Venture Partners. Based in Durham, NC, Clinverse is a provider of automated financial management technology solutions for clinical trials.

Atlas Venture leads seed round for Lysosomal Therapeutics

Lysosomal Therapeutics has secured $4.8 million in seed funding. Atlas Venture led the round with participation from Hatteras Venture Partners, Lilly Ventures, Sanofi-Genzyme BioVentures, Roche Venture Fund, Partners Innovation Fund and Orion Equity Partners. Headquartered in Cambridge, Mass., Lysosomal Therapeutics develops molecules to be used to treat neurodegenerative diseases.

Santen and Clearside Biomedical Enter into Research and Financial Pact

Santen, an Emeryville, Calif.-based subsidiary of Japan-based Santen Pharmaceuticals, has entered into a research collaboration agreement with Clearside Biomedical of Alpharetta, Georgia, a company in which Santen, along with other financial backers, is also making an investment. Specifically, Clearside’s “microinjection platform,” which provides access to the retina and choroid, just attracted $7.9 million in fresh funding from Santen, Mountain Group Capital, Hatteras Venture Partners, Georgia Research Alliance Fund, and Kenan Flagler Business School Private Equity Fund.

NXT Capital Backs Clinipace Worldwide’s Acquisition of Paragon Biomedical

NXT Capital’s venture finance group has provided financing to support Clinipace Worldwide’s acquisition of Paragon Biomedical. Digital contract research organization Clinipace is headquartered in Morrisville, North Carolina and is backed by Morgan Stanley Expansion Capital, Hatteras Venture Partners, Brooke Private Equity, Osage Venture Partners and Mario Family Partners.

Hatteras Venture Leads $3.8 Mln Round for Clinverse

Clinverse said Monday that it has closed $3.8 million in Series B round of funding led by Hatteras Venture Partners. Vital Financial also participated in the round. Raleigh, N.C.-based Clinverse provides cloud-based financial management and payment services for the clinical trials industry. PRESS RELEASE Clinverse, Inc., the global cloud-based ecommerce platform provider for clinical trials, […]

SugarSync Inks $15M Series D

SugarSync, whose free service allows you to sync your data across computers, mobile phones and other devices, has raised $15 million in Series D financing. New investor Coral Group led the round, with existing investors Draper Fisher Jurvetson, Sigma Partners, Hatteras Venture Partners and Hercules participating. The company has raised a total of $50 million […]

Clinipace Worldwide Seals $15M

Clinipace Worldwide, a digital clinical research organization, has raised $15 million in Series C financing. Morgan Stanley Expansion Capital led the round, which included participation from Durham, N.C.-based Hatteras Venture Partners, and Boston-based Brook Private Equity Advisors. The company will use the money to expand its contract research services. The company is based in Research Triangle Park, N.C.

Slideshow: Top 10 VC Funds for What’s Shaping Up as a Weak Q3

The VC fundraising environment is looking weak, with just a smattering of announcements and regulatory filings over the past two months. Official Q3 stats won’t be released until October, but it’s not looking good from an anecdotal standpoint. Trolling through the peHUB archive, I turned up just five stories about various U.S.-based VC funds getting […]

PhaseBio Pharma Adds $15M in Series B Financing

PhaseBio Pharmaceuticals has closed a $25 million Series B round after adding $15 million in venture capital and nearly $500,000 in grants. The company, based in Malvern, Penn., is developing drugs to treat diabetes, metabolic disease and cardiovascular disease. Investors include Astellas Venture Management, Johnson & Johnson Development Corporation, Hatteras Venture Partners and Fletcher Spaght Ventures.

PE HUB Community

Join the 12515 members of PE HUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Look Who’s Tweeting

PE HUB News Briefs

RSS Feed Widget

VCJ Headlines (subscribers only)

RSS Feed Widget

Buyouts Headlines (subscribers only)

RSS Feed Widget